Chai Discovery builds AI models for designing molecules. The company describes its work as frontier artificial intelligence that predicts and reprograms the interactions between biochemical molecules, and its product as a computer-aided design suite for molecules.
The models learn the underlying principles of biochemical structure and interaction. According to the site, they let scientists design new medicines on the computer, and design new molecules from scratch rather than only screening existing ones. The site says the aim is to pursue drug targets that other methods cannot reach.
The main users are scientists and drug discovery teams at life sciences and pharmaceutical companies. The site says Chai powers drug discovery programs at the world's leading pharmaceutical companies. It lists collaborations and licence agreements with Novartis, Pfizer, Eli Lilly and argenx, and describes a research update on drug-like antibody design against challenging targets with atomic precision.
The company says it has raised $400M in a Series C round to accelerate its work. The page is built around partnerships and research announcements rather than a public product listing, so it does not describe a free tier, sign-up process or pricing. Access appears to be arranged through pharmaceutical partnerships.
The site also says the company is building a future where new medicines can be designed with the precision and speed of modern engineering, and it lists open roles for people who want to work on AI for drug discovery.
